SCHEMBL3635501

SCHEMBL3635501

CC(C)(C)OC(=O)N1CCC(=C(C#N)c2ccc3c(c2)OCO3)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 1/20 0.48
GPR183 P32249 1/20 0.46
HPGD P15428 5/20 0.43
ALDH1A1 P00352 4/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TP53 P04637 2/20 0.42
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 6/20 0.42
MGLL Q99685 1/20 0.41
POLB P06746 2/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
MMP13 P45452 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13984721 0.84 KMT2A (0.45) HPGDALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL3635503 0.82 HSD17B10 (0.43) HPGDALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL27166100 0.81 GPR119 (0.44) ALDH1A1
SCHEMBL16689787 0.81 KMT2A (0.50) CYP2C19TP53SMN1; SMN2
SCHEMBL25326420 0.80 MEN1 (0.45) MMP13
SCHEMBL5383285 0.80 KMT2A (0.43) LMNA
SCHEMBL27166187 0.80 MEN1 (0.57) HPGDHSD17B10SMN1; SMN2POLB
SCHEMBL8288524 0.79 ALDH1A1 (0.67) SCD5HPGDALDH1A1CYP1A2CYP3A4
SCHEMBL2405534 0.79 KDM4E (0.48)
SCHEMBL2847196 0.79 NPC1 (0.44) HPGDALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R SCD5 2228/4885GPR183 173/4885HPGD 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.